DBV Technologies SA To Provide An Update On Investigational Viaskin Peanut for Children Ages 4-11 Years Call Transcript
Welcome to the DBV Technologies Conference Call Webcast. My name is Darryl, and I will be your operator for today's call. (Operator Instructions) I will now turn the call over to Anne Pollak. Anne, you may begin.
Thank you. This evening, DBV technologies issued a press release that outlined the written response we received from the U.S. Food and Drug Administration related to the U.S. regulatory pathway for Viaskin Peanut, an investigational epicutaneous immunotherapy patch for peanut allergy. This release is available on the press release section of the DBV Technologies website.
Before we begin, please note that today's call may include a number of forward-looking statements, including, but not limited to, comments regarding our clinical development plans, our anticipated future interactions with regulatory agencies and our financial forecasts. These forward-looking statements are based on assumptions that are subject to risks and uncertainties that could cause the company's actual results to differ
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
